Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5948626 | 0.88 | TSHR (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4TSHR | |
| SCHEMBL23902026 | 0.83 | DNM1 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4TSHR | |
| SCHEMBL12344858 | 0.81 | — | — | |
| SCHEMBL986680 | 0.81 | — | — | |
| SCHEMBL14175020 | 0.81 | — | — | |
| SCHEMBL21126444 | 0.81 | OPRM1 (0.44) | — | |
| SCHEMBL19505899 | 0.80 | TSHR (0.32) | TSHR | |
| SCHEMBL21127215 | 0.79 | OPRM1 (0.42) | TSHR | |
| SCHEMBL24209106 | 0.79 | — | — | |
| Water SCHEMBL3058939 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2019-10-03 | — | — | US | disclosed |
| US-7893068-B2 | Macrolide compounds comprising 18,19-epoxytricosa-8,12,14-trien-11-olide derivatives; angiogenesis inhibitors; anticarcinogenic, antimetastasis, antiinflammatory, and antitumor agents; antihypoxic agents; endothelial growth factor suppressors; retinal neovascularization, diabetic retinopathy | MERCIAN CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| EP-1406910-B1 | PREPARATION METHODS OF DERIVATIVES OF BISPHOSPHONATES | UNIV PARIS 13 (FR) | 2010-01-13 | — | — | EP | disclosed |
| US-7619100-B2 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7576204-B2 | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same | MERCIAN CORPORATION (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7550503-B2 | Physiologically active substances | EISAI R& D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20080280288-A1 | Assay Method to Predict Sensitivity of Cancer Cell to Anticancer Drug | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-11-13 | — | — | US | disclosed |
| US-20080275059-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | KOTAKE YOSHIHIKO | 2008-11-06 | — | — | US | disclosed |
| US-20080255146-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7256178-B2 | Physiologically active substances | EISAI CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
| WO-2003008425-A1 | NOVEL BISPHOSPHONATE DERIVATIVES, THEIR PREPARATION METHODS AND USES | UNIVERSITE PARIS 13 (FR) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | CHRNB2 4426/4885CHRNB4 4474/4885CHRNA3 4372/4885 |
| US-20080280288-A1 | Assay Method to Predict Sensitivity of Cancer Cell to Anticancer Drug | MKI67, CDK4, CDKN1A | CHRNB2 3989/4885CHRNB4 3792/4885CHRNA3 4446/4885 |
| US-20080275059-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | HIF1A, HIF1AN, VEGFA | CHRNB2 3577/4885CHRNB4 3590/4885CHRNA3 3694/4885 |
| US-20080255146-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | HIF1A, HIF1AN, VEGFA | CHRNB2 3577/4885CHRNB4 3590/4885CHRNA3 3694/4885 |
| US-20190298750-A1 | Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto | PNP, NTPCR, TYMP | CHRNB2 4721/4885CHRNB4 4708/4885CHRNA3 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.